TON taps SCRYPT for institutional stablecoin access
The Open Network Foundation has partnered with SCRYPT to provide institutional access to USDT on the TON blockchain, targeting banks, fintechs and corporate treasury users.

Finance journalist at Grafa. Covers tech, crypto, and markets, making complex finance clear for all. Passionate about innovation and trends.
The Open Network Foundation has partnered with SCRYPT to provide institutional access to USDT on the TON blockchain, targeting banks, fintechs and corporate treasury users.
Digital asset investment products recorded $224 million in inflows last week, reversing prior outflows as markets stabilised despite geopolitical tensions.
Greatland Resources (ASX:GGP) has delivered a commanding preliminary production update for the March 2026 quarter.
Coinbase expands in Australia after securing an AFSL from ASIC, launching crypto and equity perpetuals.
Telix Pharmaceuticals (ASX:TLX) logged an 11% quarter-over-quarter increase in group revenue to US$230 million for the period ended March 31.
ARC Funds (ASX:ARC) announced a conditional agreement to acquire a 25% minority stake in the business news platform, Ausbiz Group.
SolarMax Technology (NASDAQ:SMXT), a leading integrated solar energy company, announced record financial results for the fiscal year ended December 31, 2025, marked by a near-fourfold increase in revenue and a significant expansion of its energy storage pipeline.
Gilead Sciences (NASDAQ:GILD) announced on April 7, 2026, that it has entered into a definitive agreement to acquire Tubulis GmbH, a private German biotechnology company specializing in next-generation antibody-drug conjugates (ADCs).
Academy Sports + Outdoors (NASDAQ:ASO) issued a preliminary sales update for the first quarter of fiscal 2026 on April 7, 2026, signaling a robust start to the year ahead of its scheduled Analyst Day in Katy, Texas.
Precigen (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of gene and cell therapies, has announced a significant acceleration in the commercial rollout of PAPZIMEOS™ (zopapogene imadenovec-drba), projecting first-quarter 2026 revenue to exceed $18 million.